Search the Newsreel

OrthoPediatrics to Join Canaccord Conference Aug. 12 | KIDS Stock News

OrthoPediatrics (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 9:00 a.m. ET. An audio webcast of the …

OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference

OrthoPediatrics Corp. (Nasdaq: KIDS) announced its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 am ET. An audio webcast and …

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Viatris Inc. announced that the U.S. FDA has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen patch is indicated for women of childbearing potential with a BMI below 30 kg/m² and demonstrated efficacy and a well-characterized safety profile in …

Viatris Number of Employees 2026 | Employee Count & Headcount Data

Viatris, Inc. (NASDAQ: VTRS) reported approximately 29,935 global employees as of March 2026, marking a 3.8% decline from 2023. The company is actively hiring with 474 open job postings in 2026, a 10.7% increase from 2025. Viatris's workforce is primarily located in India (43.1%), …

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS) The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how generic pharmaceuticals stocks fared in Q1, starting with …

Viatris Inc. stock rises Tuesday, outperforms market

Viatris Inc. (VTRS) stock rose 1.28% on Tuesday, closing at $17.86. This performance outpaced the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw gains. The increase marks the second consecutive day of gains for Viatris stock.

Viatris Inc (VTRS) Income Statement

This article provides the quarterly and annual income statements for Viatris Inc (VTRS), offering detailed financial data such as total revenue, cost of revenue, operating expenses, operating profit, net income, and earnings per share (EPS). It includes year-over-year percentage changes and absolute figures across …

Viatris Inc (VTRS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Viatris Inc.'s (VTRS) shareholder structure, listing major shareholders and their proportionate holdings, along with institutional ownership trends over recent quarters. It also categorizes shareholders by type and lists ETFs with significant VTRS holdings.

Viatris stock hits 52-week high at $17.68

Viatris Inc. (VTRS) stock reached a 52-week high of $17.68, reflecting strong market performance with a 90.82% surge over the past year and a 2.78% dividend yield. The pharmaceutical company is considered undervalued by InvestingPro, with recent positive news including exceeding Q1 2026 financial …

Medical device manufacturer gets a new backbone after global takeover

Chesterfield-based medical device manufacturer SpineCorporation has been acquired by the US healthcare company OrthoPediatrics Corp. The acquisition, supported by Hawsons Corporate Finance and Knights Solicitors, will expand OrthoPediatrics' presence in the specialist healthcare market. This cross-border deal marks a significant milestone for SpineCorporation, with …

Viatris, Inc. Revenue Breakdown – BX:VTRS

Viatris, Inc. (VTRS) generated 11.34 billion CHF last year, with its "Brands" segment contributing the most at 7.28 billion CHF. The company's largest revenue contribution came from Developed Markets, accounting for 4.37 billion CHF. This data provides a snapshot of Viatris's key revenue drivers …

OrthoPediatrics Corp. Revenue Breakdown – SWB:2X7

OrthoPediatrics Corp. (SWB:2X7) generated €201.23 million in revenue last year, with its Trauma and Deformity segment contributing the most at €141.59 million. The majority of the company's revenue, €158.71 million, originated from the United States. These figures highlight the company's key revenue drivers and …

KIDS|OrthoPediatrics Corp|Price:18.840|Chg%:+0.120

OrthoPediatrics Corp (KIDS) has strong fundamentals and high growth potential, with its revenue averaging 58.91% year-on-year growth over the past three years. The stock is considered fairly valued and has a high institutional ownership, with multiple analysts rating it as a "Buy" with a …

OrthoPediatrics sets Aug. 4 date for second-quarter results

OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after market close. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results, with a live and …

PFE5003244 Bond Risk Profile

This article provides a risk profile for the PFE5003244 bond issued by Viatris Inc., maturing on June 22, 2030, with a 2.7% coupon rate. It focuses on key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors …

PFE5282056 Bond Profile — Key Metrics

This article provides a detailed profile of the PFE5282056 bond issued by Viatris, Inc. Key metrics include its 2.7% coupon rate, maturity date of June 22, 2030, and an outstanding amount of $1.45 billion. The piece also gives an overview of Viatris Inc., describing …

Viatris Inc. stock rises Thursday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.59% to $17.28 on Thursday, outperforming the broader market which saw the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) decline. The company's stock closed 2.23% below its 52-week high of $17.68. This rise occurred during …

Viatris, Inc. (VIA) Q2 2023 Earnings Report - Results, Call & Slides

Viatris, Inc. (VIA) reported its Q2 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of €0.66 against a consensus of €0.62, and actual revenue of €3.43 billion against an expected €3.38 billion. The report includes details from the …

Viatris’ Quarterly Earnings Preview: What You Need to Know

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global healthcare company that develops, manufactures, and markets branded medicines, generic drugs, complex generics, biosimilars, and over-the-counter products. Valued at a market cap of $19.8 billion, Viatris …

PFE5003244 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the PFE5003244 bond issued by Viatris Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 2.70%, with the next payment expected on December 22, 2026. The article highlights how to …

OrthoPediatrics to report Q2 2026 financial results on August 4

OrthoPediatrics Corp. is scheduled to release its financial results for the second quarter of 2026 on August 4, 2026, after the market closes. The company, which specializes in pediatric orthopedics, will hold a conference call on the same day at 4:30 p.m. ET to …

FDA slaps Sanofi, Viatris with Untitled Letters over promotional emails, TV ad

The FDA has issued Untitled Letters to Sanofi and Viatris regarding their promotional materials. Viatris received a letter for a TV ad about Tobi Podhaler, which implied broader usage than approved, while Sanofi was cited for promotional emails for Beyfortus that misrepresented its RSV …

Diatreme Resources (ASX:DRX) Climbs 9.09% as Market Tracks Silica Development

Diatreme Resources (ASX:DRX) Shares Rise 9%: What’s Driving Interest in the Mineral Explorer?

Precision Trading with Orthopediatrics Corp. (KIDS) Risk Zones

This article analyzes Orthopediatrics Corp. (KIDS) with a focus on precision trading, highlighting a weak near-term sentiment that could lead to bearish positioning. It outlines three distinct AI-generated trading strategies including position, momentum breakout, and risk hedging, tailored for different risk profiles. The analysis …

KIDS Q1 2026 Earnings: EPS Surprise but Stock Declines on Revenue Omission - One-Time Gain Impact

Is Viatris (VTRS) Reframing Its Musculoskeletal Strategy Through the AAOS Pain Management Partnership?

Viatris (VTRS) has partnered with the American Academy of Orthopaedic Surgeons (AAOS) to launch an online Pain Management Resource Center, reflecting its strategic focus on musculoskeletal pain care. While this initiative aligns with Viatris's push into higher-value pain treatments, the article highlights that the …

PFE5003242 Bond Profile — Key Metrics

This article provides a bond profile for PFE5003242, a Viatris Inc. bond with a 2.3% coupon maturing on June 22, 2027. It details key metrics such as issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The profile also includes …

Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon

Khaitan & Co advised Viatris Inc. on the secondary sale of its shares in Biocon Limited. The transaction involved a total consideration of INR 3680 crore (USD 385.9 million) through stock exchange sales. The legal team from Khaitan & Co was led by Rabindra …

Viatris stock hits 52-week high at $17.54 By Investing.com

Viatris Inc. stock reached a 52-week high of $17.53, reflecting a 94% increase over the past year and 41% year-to-date returns. InvestingPro analysis suggests the stock is undervalued, with further upside potential. The company recently reported strong Q1 2026 financial results exceeding analyst expectations …

KIDS5867370 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the OrthoPediatrics Corp. bond KIDS5867370, detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.75%, with the next payment anticipated on August 17, 2026. It highlights the importance of understanding bond …

KIDS5867370 Bond Profile — Key Metrics

This article provides a bond profile for OrthoPediatrics Corp. 4.75% 15-FEB-2030 (KIDS5867370). It details key metrics such as issue date, maturity date, coupon rate, and issuer information. The bond has an outstanding amount of 0.00 USD and a face value of 1,000.00 USD.

OrthoPediatrics Corp. (NASDAQ: KIDS) holders disclose 3.2% ownership stake

Integrated Core Strategies (US) LLC and related Millennium entities, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have reported a beneficial ownership stake of 3.2% in OrthoPediatrics Corp. (NASDAQ: KIDS) through a Schedule 13G/A filing. Integrated Core Strategies holds 811,042 …

Viatris Inc. stock rises Wednesday, outperforms market

Viatris Inc. (VTRS) stock increased by 2.27% on Wednesday, closing at $16.68. The rise came during an overall positive trading session, with the S&P 500 Index gaining 0.38% and the Dow Jones Industrial Average gaining 0.29%. The stock is currently 4.85% below its 52-week …

Viatris range-top rebound lacks a volume kicker despite a 44-week Trend Signal

Viatris rose 6.2% for the week and remains high in its 52-week range, but average participation and an undecided expectancy read keep the setup balanced.

Diatreme Resources (ASX:DRX) Completes Key Sibelco Transaction as Northern Silica Strategy Advances